A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back

Autor:	D. Ceraulo, Silvia Zanon, G. Pepe, Chiara Pircher, A. Costantino, Stefano Crippa, Massimo Falconi, Michele Reni, Luca Gianni, C. Fugazza, M. Chiaravalli, Claudio Doglioni, Gianpaolo Balzano, Paolo Passoni, Paolo Giorgio Arcidiacono, Roberto Nicoletti
Rok vydání:	2016
Předmět:	Cisplatin Oncology medicine.medical_specialty business.industry Hematology medicine.disease Gemcitabine Capecitabine Regimen Borderline resectable Internal medicine medicine Adenocarcinoma business medicine.drug Nab-paclitaxel
Zdroj:	Annals of Oncology. 27:iv17
ISSN:	0923-7534
DOI:	10.1093/annonc/mdw333.01
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ac639d94af5e4405406916c2dd57afb4 https://doi.org/10.1093/annonc/mdw333.01 Zobrazit plný text záznamu